Consistent with these findings, monomethylated selenium (MeSe) has been shown to reduce the growth of LNCaP human prostate cancer xenografts, accompanied by a decrease in androgen receptor and prostate-specific antigen expression [109]. The gene discussed is AR; the disease is prostate carcinoma.